Circulating tumour cells as a predictive factor for response to systemic chemotherapy in patients with advanced colorectal cancer

Molecular Oncology

Volumn 2, Issue 4, 2008, Pages 349-355

  Lankiewicz, Silke ^a   Zimmermann, Silke ^a   Hollmann, Christiane ^b   Hillemann, Tina ^c   Greten, Tim F ^c  

^a AdnaGen AG   (Germany)

^b GLAXOSMITHKLINE   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Circulating tumour cells; Colorectal cancer; CTC; EGFR; EGFR variants

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CIRCULATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR CELL; TUMOR REGRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD CELLS; COLORECTAL NEOPLASMS; DIAGNOSTIC TECHNIQUES AND PROCEDURES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; TREATMENT FAILURE;

EID: 56749180772     PISSN: 15747891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molonc.2008.09.001     Document Type: Article

References (34)

1. Azuma M., Danenberg K.D., Iqbal S., El-Khoueiry A., Zhang W., Yang D., Koizumi W., Saigenji K., Danenberg P.V., and Lenz H.J. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin. Colorectal Cancer 6 (2006) 214-218
2. Bralet M.P., Paule B., Adam R., and Guettier C. Loss of epidermal growth factor receptor expression in lymph node and liver metastases of colon carcinoma. J. Clin. Oncol. 23 (2005) 5844-5845
3. Budd G.T., Cristofanilli M., Ellis M.J., Stopeck A., Borden E., Miller M.C., Matera J., Repollet M., Doyle G.V., Terstappen L.W., et al. Circulating tumor cells versus imaging - predicting overall survival in metastatic breast cancer. Clin. Cancer Res. 12 (2006) 6403-6409
4. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23 (2005) 1803-1810
5. Cohen S.J., Alpaugh R.K., Gross S., O'Hara S.M., Smirnov D.A., Terstappen L.W., Allard W.J., Bilbee M., Cheng J.D., Hoffman J.P., et al. Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin. Colorectal Cancer 6 (2006) 125-132
6. Cristofanilli M., Hayes D.F., Budd G.T., Ellis M.J., Stopeck A., Reuben J.M., Doyle G.V., Matera J., Allard W.J., Miller M.C., et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J. Clin. Oncol. 23 (2005) 1420-1430
7. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 (2004) 337-345
8. Cunningham M.P., Essapen S., Thomas H., Green M., Lovell D.P., Topham C., Marks C., and Modjtahedi H. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int. J. Oncol. 27 (2005) 317-325
9. Elshimali Y.I., and Grody W.W. The clinical significance of circulating tumor cells in the peripheral blood. Diagn. Mol. Pathol. 15 (2006) 187-194
10. Frederick L., Wang X.Y., Eley G., and James C.D. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60 (2000) 1383-1387
11. Ge H., Gong X., and Tang C.K. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int. J. Cancer 98 (2002) 357-361
12. Guller U., Zajac P., Schnider A., Bosch B., Vorburger S., Zuber M., Spagnoli G.C., Oertli D., Maurer R., Metzger U., et al. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann. Surg. 236 (2002) 768-775
13. Hayes D.F., Cristofanilli M., Budd G.T., Ellis M.J., Stopeck A., Miller M.C., Matera J., Allard W.J., Doyle G.V., and Terstappen L.W. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin. Cancer Res. 12 (2006) 4218-4224
14. Italiano A., Saint-Paul M.C., Caroli-Bosc F.X., Francois E., Bourgeon A., Benchimol D., Gugenheim J., and Michiels J.F. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: biological and clinical implications. Ann. Oncol. 16 (2005) 1503-1507
15. Ji H., Zhao X., Yuza Y., Shimamura T., Li D., Protopopov A., Jung B.L., McNamara K., Xia H., Glatt K.A., et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc. Natl. Acad. Sci. USA 103 (2006) 7817-7822
16. Kang Y., and Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118 (2004) 277-279
17. Koch M., Kienle P., Kastrati D., Antolovic D., Schmidt J., Herfarth C., von Knebel Doeberitz M., and Weitz J. Prognostic impact of hematogenous tumor cell dissemination in patients with stage II colorectal cancer. Int. J. Cancer 118 (2006) 3072-3077
18. Lankiewicz, S., 2006. Novel tumor marker. EP1930345 [patent online]. Available from URL: http://v3.espacenet.com/origdoc?DB=EPODOC&;IDX=EP1930345& F=0&QPN=EP1930345.
19. Lankiewicz, S., Fehm, T., 2007. Expression of epidermal growth factor receptor (EGFR) and N-terminal variants on circulating tumor cells in metastasized breast cancer patients, in: Proceedings of the 6th International Symposium on Minimal Residual Cancer. Hamburg, Germany, 70 (#036).
20. Lankiewicz, S., Rother, E., Zimmermann, S., Hollmann, C., Korangy, F., Greten, T.F., in press. Tumour-associated transcripts and EGFR deletion variants in colorectal cancer in primary tumour, metastases and circulating tumour cells. Cell. Oncol. (in press).
21. Meropol N.J. Epidermal growth factor receptor inhibitors in colorectal cancer: it's time to get back on target. J. Clin. Oncol. 23 (2005) 1791-1793
22. Molnar B., Sipos F., Galamb O., and Tulassay Z. Molecular detection of circulating cancer cells. Role in diagnosis, prognosis and follow-up of colon cancer patients. Dig. Dis. 21 (2003) 320-325
23. Moscatello D.K., Holgado-Madruga M., Godwin A.K., Ramirez G., Gunn G., Zoltick P.W., Biegel J.A., Hayes R.L., and Wong A.J. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res. 55 (1995) 5536-5539
24. Nygren P., Sorbye H., Osterlund P., and Pfeiffer P. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report. Acta Oncol. 44 (2005) 203-217
25. Olapade-Olaopa E.O., Moscatello D.K., MacKay E.H., Horsburgh T., Sandhu D.P., Terry T.R., Wong A.J., and Habib F.K. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br. J. Cancer 82 (2000) 186-194
26. Pfeiffer P., Qvortrup C., and Eriksen J.G. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 26 (2007) 3661-3678
27. Scartozzi M., Bearzi I., Berardi R., Mandolesi A., Fabris G., and Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J. Clin. Oncol. 22 (2004) 4720-4726
28. Spindler K.L., Olsen D.A., Nielsen J.N., Brandslund I., Poulsen H.S., Villingshoj M., and Jakobsen A. Lack of the type III epidermal growth factor receptor mutation in colorectal cancer. Anticancer Res. 26 (2006) 4889-4893
29. Thorban S., Rosenberg R., Maak M., Friederichs J., Gertler R., and Siewert J.R. Impact of disseminated tumor cells in gastrointestinal cancer. Expert Rev. Mol. Diagn. 6 (2006) 333-343
30. Vallböhmer D., Zhang W., Gordon M., Yang D.Y., Yun J., Press O.A., Rhodes K.E., Sherrod A.E., Iqbal S., Danenberg K.D., et al. Molecular determinants of cetuximab efficacy. J. Clin. Oncol. 23 (2005) 3536-3544
31. Wikstrand C.J., Hale L.P., Batra S.K., Hill M.L., Humphrey P.A., Kurpad S.N., McLendon R.E., Moscatello D., Pegram C.N., Reist C.J., et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res. 55 (1995) 3140-3148
32. Zhang W., Gordon M., and Lenz H.J. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann. Med. 38 (2006) 545-551
33. Zieglschmid V., Hollmann C., Gutierrez B., Albert W., Strothoff D., Gross E., and Böcher O. Combination of immunomagnetic enrichment with multiplex RT-PCR analysis for the detection of disseminated tumor cells. Anticancer Res. 25 (2005) 1803-1810
34. Zieglschmid V., Hollmann C., Mannel J., Albert W., Jaeschke-Melli S., Eckstein B., Hillemann T., Greten T.F., Gross E., and Böcher O. Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer. Anticancer Res. 27 (2007) 1823-1832